As CROs around the world weigh the benefits of developing their own therapies, South Korea's SillaJen has signed a deal worth up to $150 million to acquire former client Jennerex and inherit the company's Phase III-ready cancer vaccine.
Teva may not have actually planted a "for sale" sign on its front yard, but now that CEO Jeremy Levin has left the scene of many accidents some top analysts are offering to advertise it as a takeover candidate.
A few months after Jennerex and its partner Transgene reported that their oncolytic cancer vaccine Pexa-Vec flunked a Phase IIb endpoint on overall survival in liver cancer, the private South Korean CRO SillaJen has stepped in to buy the company in a deal worth up to $150 million at the high end.
Most drugmakers say mergers are what they need to become bigger and more profitable. South Africa's Adcock Ingram say it needs a proposed merger just to survive.
Italian drugmaker Menarini is looking to grow its operations in India. It is bringing some new products to market there but would like to buy some established drug brands if it can find them at the right price.
Thermo Fisher is plodding along with its blockbuster agreement to trade $13.6 billion for competitor Life Technologies, picking up European Commission approval on the condition that it sheds a few business units.
Two buyout firms are duking it out for LTS Lohmann, a drug-patch maker partly owned by Novartis, Reuters reports. Now that the dust has settled on first-round bids, which were due last month, Wendel and Nordic Capital are still in the running for a deal worth about $1.6 billion.
U.K. orthopedics giant Smith & Nephew has been riding its checkbook into emerging markets all year, and now the company has signed a deal to pick up a share of its Brazilian wound care partner with an eye on vertical integration.
When Bayer CEO Marijn Dekkers stepped into the job in 2010, he had a trove of cash, and he promised to spend a big chunk on deals. A $23 billion chunk, in fact. Since then, the German conglomerate hasn't exactly been audacious in the M&A arena. Bayer has snapped up a healthcare company or three, but it's quick to back away if a price gets too rich.
Earlier this year, Bayer happily heralded the FDA's approval of Xofigo for castration-resistant prostate cancer as an important milestone for its steadily growing portfolio of cancer therapies. And now the German pharma company has set its sights on bagging Algeta--the Norwegian company that discovered the therapy and subsequently partnered with Bayer--for $2.4 billion.